Molecular structure of (±)-SLV 319, CAS Number: 362519-49-1
(±)-SLV 319 (CAS 362519-49-1)
Alternate Names:
Ibipinabant
Application:
(±)-SLV 319 is a mixture of the CB1 antagonist SLV 319 and its distomer
CAS Number:
362519-49-1
Molecular Weight:
487.40
Molecular Formula:
C23H20Cl2N4O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
(±)-SLV 319 emerges as a promising and potent inhibitor of the enzyme fatty acid amide hydrolase (FAAH), belonging to the class of synthetic cannabinoids that mimic the effects of cannabis. In vitro studies have contributed to our understanding of (±)-SLV 319′s mechanism of action. It has been observed that (±)-SLV 319 can inhibit the activity of FAAH in cell culture systems. Furthermore, these studies have shown that (±)-SLV 319 reduces the production of pro-inflammatory cytokines in cell culture systems. By binding to the FAAH enzyme responsible for breaking down the endocannabinoid anandamide, (±)-SLV 319 effectively inhibits its activity. This inhibition leads to increased levels of anandamide in the body, potentially contributing to the therapeutic effects of (±)-SLV 319.
(±)-SLV 319 (CAS 362519-49-1) References
- Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. | Lange, JH., et al. 2004. J Med Chem. 47: 627-43. PMID: 14736243
- Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. | Lange, JH., et al. 2005. Bioorg Med Chem Lett. 15: 4794-8. PMID: 16140010
- Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. | Stern, E., et al. 2006. J Med Chem. 49: 70-9. PMID: 16392793
- Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole. | Srivastava, BK., et al. 2008. Bioorg Med Chem Lett. 18: 963-8. PMID: 18207393
- Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. | Janero, DR. and Makriyannis, A. 2009. Expert Opin Emerg Drugs. 14: 43-65. PMID: 19249987
- Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. | Heal, DJ., et al. 2009. Br J Clin Pharmacol. 68: 861-74. PMID: 20002080
- Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists. | Gullapalli, S., et al. 2010. Neuropharmacology. 58: 1215-9. PMID: 20214912
- Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies. | Yang, Y., et al. 2011. Bioorg Med Chem Lett. 21: 6856-60. PMID: 21962575
- JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. | Chorvat, RJ., et al. 2012. Bioorg Med Chem Lett. 22: 6173-80. PMID: 22959249
- Peripherally restricted CB1 receptor blockers. | Chorvat, RJ. 2013. Bioorg Med Chem Lett. 23: 4751-60. PMID: 23902803
- A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. | Hsiao, WC., et al. 2015. Diabetes Obes Metab. 17: 495-504. PMID: 25656402
- Organophosphate Agent Induces ADHD-Like Behaviors via Inhibition of Brain Endocannabinoid-Hydrolyzing Enzyme(s) in Adolescent Male Rats. | Ito, Y., et al. 2020. J Agric Food Chem. 68: 2547-2553. PMID: 31995978
- Renal Proximal Tubule Cell Cannabinoid-1 Receptor Regulates Bone Remodeling and Mass via a Kidney-to-Bone Axis. | Baraghithy, S., et al. 2021. Cells. 10: PMID: 33671138
- Targeting the endocannabinoid system in diabesity: Fact or fiction? | Deeba, F., et al. 2021. Drug Discov Today. 26: 1750-1758. PMID: 33781949
- Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition. | Jaiquel Baron, S., et al. 2021. Theranostics. 11: 5077-5091. PMID: 33859735
Inhibitor of:
CB1, CBS, Clb1, and MCH-2R.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(±)-SLV 319, 1 mg | sc-222317 | 1 mg | $30.00 | |||
(±)-SLV 319, 5 mg | sc-222317A | 5 mg | $131.00 |